Sutro Biopharma, Inc. (STRO)

Sutro Biopharma implemented a 1-for-10 reverse stock split in December 2025 to regain Nasdaq compliance. In February 2026, the company completed a $110.0 million public offering, leading to an 11.9% stock jump. Positive preclinical data and clinical advancements have driven stock surges, including a presentation at AACR 2026 and the initiation of Phase 1 dosing for STRO-004. Sutro reported its full-year 2025 financial results on March 23, 2026. Several analysts have upgraded Sutro Biopharma's stock, with price objective increases from Deutsche Bank Aktiengesellschaft and Citizens Jmp, and a "Strong-Buy" rating from Lifesci Capital. As of May 5, 2026, the stock price was $37.32, with significant increases over the past year and year-to-date.

Specific details regarding demand seasonality for Sutro Biopharma's products and services are not explicitly provided. As a clinical-stage biotechnology company, its revenue is primarily driven by collaboration agreements and milestone payments rather than direct product sales. Stock price can be influenced by events such as clinical trial readouts, regulatory milestones, and financial reporting.

Sutro Biopharma, Inc. is a clinical-stage oncology company focused on discovering, developing, and manufacturing next-generation protein therapeutics, primarily antibody-drug conjugates (ADCs), for cancer and autoimmune disorders, operating within the Biotechnology industry. Sutro Biopharma utilizes its XpressCF and XpressCF+ platforms to engineer ADCs, enabling site-specific conjugation, high drug-to-antibody ratios, and dual-payload ADCs. Major products and pipeline candidates include STRO-004, STRO-006, STRO-227, STRO-002 (luveltamab tazevibulin, or luvelta), STRO-001, STRO-003, and partnered programs with Astellas and Vaxcyte.

Sutro Biopharma, Inc. is headquartered in South San Francisco, California, United States, and has a cGMP manufacturing facility in San Carlos, CA.

Sutro Biopharma's brand reputation has been influenced by challenges, including a restructuring in September 2025 and the deprioritization of STRO-002 due to a Grade 5 febrile neutropenia event. However, there have been positive shifts, with optimism surrounding next-generation ADC programs like STRO-004 and STRO-006. Promising preclinical data at AACR 2026 and analyst upgrades have boosted investor confidence.

Institutional investors hold between 33.79% and 48.27% of Sutro Biopharma's shares, while insiders hold 92.23%. Major institutional owners include Affinity Asset Advisors, LLC, Kynam Capital Management, LP, Millennium Management Llc, Vanguard Group Inc, Acadian Asset Management Llc, Velan Capital Investment Management LP, Vestal Point Capital, LP, Balyasny Asset Management Llc, Samsara BioCapital, LLC, Adage Capital Partners Gp, L.l.c., Merck & Co., Inc., State Street Corp., Invesco Ltd., and RA Capital Management L.P. Major individual owners (insiders) include Merck Co Inc, Skyline Venture Partners V LP, Daniel Janney, Alta Partners VIII LP, Svlsf V LLC, Michael Jay Ross, Celgene Corp, and William J. Newell.